Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes

Individuals with type 2 diabetes who are also immunocompromised may require multiple doses of the pneumococcal conjugate vaccine (PCV) to maintain protection, according to recent findings. The research indicates that a standard vaccination schedule may not provide sufficient long-term immunity in this specific population. The study focused on individuals with both type 2 diabetes (T2D) and compromised immune systems. Researchers observed that these individuals may need more than the typical single dose of PCV to ensure sustained protection against pneumococcal infections. This suggests that the standard vaccination protocol might not be adequate for those with this dual condition, highlighting a potential need for adjusted immunization strategies.

Newsflash | Powered by GeneOnline AI
Date: April 19, 2025

Related posts:

Blood Disorder Management: Current Treatments Include Phlebotomy to Reduce Hematocrit AI Identifies Existing Medications for Alzheimer’s, Parkinson’s & Epilepsy Treatment, DrugPatentWatch Reports International Research Teams Focus on Affordable Generics to Address Rising Healthcare Costs. Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後